![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1397154
±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½º ½ÃÀå : »çÀÌŬ À¯Çüº°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¹× ¿¹Ãø(2023-2030³â)Donor Egg IVF Services Market, By Cycle Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030 |
±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½º ½ÃÀå ±Ô¸ð´Â 2022³â 24¾ï 820¸¸ ´Þ·¯¿¡ ´ÞÇß°í, 2023³âºÎÅÍ 2030³â±îÁö CAGR 11.9%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½º ½ÃÀå - ½ÃÀå ¿ªÇÐ
ºÒÀÓ·ü »ó½Â ¹× ÀӽŠÁö¿¬ °æÇâ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» À̲ø °ÍÀ¸·Î ¿¹»óµË´Ï´Ù
ÀӽŠÁö¿¬ Áõ°¡´Â Á¾Á¾ ¾î¸Ó´ÏÀÇ °í·ÉÈ¿Í °ü·ÃÀÌ ÀÖÀ¸¸ç ºÒÀÓÀÇ ÁÖ¿ä ¿äÀÎÀÌ µÇ¾ú½À´Ï´Ù. ºÒÀÓÁõÀº Á¡Á¡ ´õ ¸¹Àº °³Àΰú ºÎºÎ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¼¼°è °Ç°»óÀÇ ½É°¢ÇÑ ¹®Á¦ÀÔ´Ï´Ù. ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È, ȯ°æÀÇ ¿µÇâ, ±âÃÊÀûÀÎ °Ç°»óÅ µî ´Ù¾çÇÑ ¿äÀÎÀÌ ºÒÀÓÁõÀÇ ¿øÀÎÀÌ µÇ¾î ºÒÀÓÁõ¿¡ ´ëóÇÏ´Â ÇØ°áÃ¥ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¼¼°èº¸°Ç±â±¸¿¡ µû¸£¸é ºÒÀÓÀ» °æÇèÇÏ´Â »ç¶÷Àº ¸Å¿ì ¸¹À¸¸ç ¼ºÀÎ Àα¸ÀÇ ¾à 17.5%(¼¼°èÀÇ ¾à 6¸í Áß 1¸í)°¡ ºÒÀÓ¿¡ ½Ã´Þ¸®°í ÀÖ½À´Ï´Ù. À̰ÍÀº ºÒÀÓ Ä¡·á°¡ ÇÊ¿äÇÑ »ç¶÷µéÀ» À§ÇØ ÇÕ¸®ÀûÀÎ °¡°ÝÀ¸·Î °íǰÁúÀÇ ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Çâ»ó½ÃŰ´Â ±ä±ÞÇÑ Çʿ伺À» µ¸º¸ÀÌ°Ô ÇÕ´Ï´Ù. ¼¼°èÀÇ ºÒÀÓ·ü »ó½ÂÀº ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF)°ú °°Àº º¸Á¶»ý½Ä±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ÃËÁøÇÕ´Ï´Ù. ¶ÇÇÑ, ±âÁõ ³ÀÚÀÇ »ç¿ëÀ» Æ÷ÇÔÇÑ Àӽżº ¿ÂÁ¸¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF)°ú °ü·ÃµÈ °í°¡ÀÇ ºñ¿ëÀº ¸¹Àº °³Àΰú Ä¿Çÿ¡°Ô Å« À庮ÀÌ µÉ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ ¼ºñ½º¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Á¦ÇÑ ÇÒ ¼ö ÀÖ½À´Ï´Ù.
±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½º ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®
´ç»çÀÇ ¸®¼Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°èÀÇ ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½º ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â)¿¡ ¾à 11.9%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
»çÀÌŬ À¯Çü¿¡ ±âÃÊÇÑ ¼¼ºÐÈ¿¡¼´Â µ¿°á ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF) »çÀÌŬÀÌ 2022³â¿¡ ÃÖ´ë ½ÃÀå Á¡À¯À²À» ³ªÅ¸³½ °ÍÀ¸·Î Æò°¡µÇ¾ú½À´Ï´Ù.
¿ëµµº°·Î´Â 2022³â¿¡´Â ºÒÀÓ Ä¡·á Ŭ¸®´ÐÀÌ ÁÖ¿ä À¯ÇüÀÌ µÇ¾ú½À´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2022³â ¸ÅÃâÀ» À̲ø¾ú½À´Ï´Ù.
¼¼°èÀÇ ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½º ½ÃÀåÀº »çÀÌŬ À¯Çü, ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐȵ˴ϴÙ.
½ÃÀåÀº »çÀÌŬ À¯Çü¿¡ µû¶ó ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. : ½Å¼±ÇÑ ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF) »çÀÌŬ°ú ³Ãµ¿ ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF) »çÀÌŬÀÔ´Ï´Ù. ½ÃÀåÀº ³Ãµ¿ ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF) »çÀÌŬ¿¡ ÀÇÇØ Áö¹èµË´Ï´Ù. ³Ãµ¿ ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF) »çÀÌŬÀº ŸÀָ̹鿡¼ À¯¿¬¼ºÀ» Áõ°¡½ÃÄÑ ±âÁõÀÚ¿Í ¼ö·ÉÀÎ »çÀÌŬ »çÀÌÀÇ ´õ ³ªÀº Á¶Á¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ ÀåÁ¡Àº °èȹ°ú ½ºÄÉÁÙ¸µ¿¡ ¸Å¿ì À¯¿ëÇÕ´Ï´Ù. °Ô´Ù°¡, ³Ãµ¿ ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF) »çÀÌŬÀº ±âÁ¸ÀÇ ½Å¼±ÇÑ ±âÁõ ³ÀÚ »çÀÌŬ°ú ºñ±³ÇÒ ¶§ ´õ ºñ¿ë È¿À²ÀûÀÎ °æÇâÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±âÁõÀÚ¿Í ¼ö·ÉÀÎ °£ÀÇ »çÀÌŬ µ¿±âȰ¡ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù.
½ÃÀåÀº ¿ëµµ¿¡ µû¶ó µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. : ºÒÀÓ Ä¡·á Ŭ¸®´Ð, º´¿ø, ¼ö¼ú¼¾ÅÍ, ÀÓ»ó ¿¬±¸ ±â°üÀÔ´Ï´Ù. ½ÃÀåÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ´Â °ÍÀº ºÒÀÓ Ä¡·á Ŭ¸®´ÐÀÔ´Ï´Ù. ÀÌ Å¬¸®´ÐÀº ÀϹÝÀûÀ¸·Î ³ÀÚ ±âÁõÀÚÀÇ Æò°¡¿Í ¼±ÅÃ, ±âÁõÀÚ¿Í ¼ö·ÉÀÎ »çÀÌÀÇ »çÀÌŬ µ¿±âÈ, ½ÇÁ¦ ü¿Ü¼öÁ¤(IVF) ÀýÂ÷¸¦ Æ÷ÇÔÇÏ¿© ±âÁõ ³ÀÚ¸¦ À§ÇÑ ±¤¹üÀ§ÇÑ ÇÁ·Î±×·¥À» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ºÒÀÓ Ä¡·á Ŭ¸®´ÐÀº Á¾Á¾ ³ÀÚ Á¦°ø¾÷ü¿Í ¼ö·ÉÀÎ ¸ðµÎ¿¡°Ô »ó´ã ¼ºñ½º¸¦ Á¦°øÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, ³ÀÚ Á¦°ø°ú ü¿Ü¼öÁ¤(IVF) °úÁ¤À» ÅëÇØ ½É¸®Àû Áö¿ø ¹× ¾È³»¸¦ Æ÷ÇÔÇÕ´Ï´Ù.
±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½º ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®
±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½º ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ Áö¸®ÀûÀ¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ¶ÇÇÑ »ç¾÷¿¡ ±â¿©ÇÏ´Â ±¹°¡·Î ³ª´µ¾îÁ® ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â ÷´Ü ÇコÄɾî ÀÎÇÁ¶ó ¹× ü¿Ü¼öÁ¤(IVF)ÀÇ ¼º°ø·üÀÌ ³ô±â ¶§¹®¿¡ ½ÃÀå ¼ºÀåÀ» À̲ø °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ƯÈ÷ ¹Ì±¹°ú ij³ª´Ù´Â ÀÇ·á ÀÎÇÁ¶ó°¡ È®¸³µÇ¾î ÀÖÀ¸¸ç ½ÇÇè½Ç ±â¼ú, À¯ÀüÀÚ °Ë»ç, µ¿°áº¸Á¸ÀÇ Áö¼ÓÀûÀÎ Áøº¸°¡ ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½ºÀÇ ¼º°ø¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æ °ü¸®¼¾ÅÍÀÇ 2021³â ºÒÀÓÄ¡·á Ŭ¸®´Ð ¼º°ø·ü º¸°í¼¿¡ µû¸£¸é ¹Ì±¹ÀÇ 453°³ º¸°í Ŭ¸®´Ð¿¡¼ 238,126¸íÀÇ È¯ÀÚ°¡ 413,776ȸÀÇ ART »çÀÌŬÀ» ´Þ¼ºÇÏ¿´À¸¸ç, °á°úÀûÀ¸·Î 91,906¸íÀÇ Ãâ»ê°ú 97,128¸íÀÇ Ãâ»ý¾Æ°¡ µÇ¾ú½À´Ï´Ù. ¿¹Ãø±â°£¿¡¼´Â ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF) ±â¼úÀÇ Áøº¸·Î À¯·´°ú ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤ ¼ºñ½º ½ÃÀåÀº »ý½Äº¸Á¶ ÀÇ·á±â¼ú(ART)À» Á¦°øÇÏ°í ºÒÀÓ Ä¡·á¸¦ À§ÇÑ ±âÁõ ³ÀÚÀÇ »ç¿ëÀ» ÃËÁøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ºÒÀÓ Ä¡·á Ŭ¸®´Ð°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ½À´Ï´Ù. »ý½Äº¸Á¶ ÀÇ·á±â¼úÀ» Àü¹®À¸·Î ÇÏ´Â Vitrolife¿Í °°Àº ±â¾÷Àº ±âÁõ ³ÀÚ¸¦ Æ÷ÇÔÇÑ Ã¼¿Ü¼öÁ¤(IVF)À» À§ÇÑ Á¦Ç°°ú ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ±â¾÷µéÀº ü¿Ü¼öÁ¤(IVF) °úÁ¤ÀÇ ±â¼úÀû Ãø¸é¿¡ ±â¿©ÇÕ´Ï´Ù. ±âÁõ ³ÀÚ Ã¼¿Ü¼öÁ¤(IVF) ½ÃÀåÀÇ °æÀïÀº Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß ³ë·Â¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. µ¿°áº¸Á¸±â¼ú °³¼±°ú ¼º°ø·ü Çâ»ó µî ±â¼úÇõ½Å¿¡ ÅõÀÚÇÏ´Â ±â¾÷ÀÌ °æÀï¿ìÀ§¿¡ ¼·´Ï´Ù. ±× ÀÏ·Ê·Î Cooper Companies´Â 2021³â 12¿ù 17ÀÏ ºÒÀÓ Ä¡·á¸¦ À§ÇÑ ³ÀÚ ¹× Á¤ÀÚ Á¦°ø, ºÒÀÓ Ä¡·á¿ë µ¿°áº¸Á¸ ½Ã¼³, ½Å»ý¾Æ Áٱ⠼¼Æ÷ º¸Á¸(Á¦´ëÇ÷ ¹× Á¦´ë Á¶Á÷)À» Á¦°øÇÏ´Â ´ë±â¾÷, Generate Life Sciences Àμö°¡ ¾à 16¾ï ´Þ·¯·Î ¿Ï·áµÇ¾ú´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.
Donor Egg IVF Services Market size was valued at USD 2408.20 Million in 2022, expanding at a CAGR of 11.9% from 2023 to 2030.
Donor egg in vitro fertilization (IVF) is a fertility treatment option that involves using eggs donated by another woman to help individuals or couples achieve pregnancy. This method is commonly used when the intended mother is unable to produce viable eggs or has a medical condition that makes using her own eggs difficult. Donor egg IVF is indicated for advanced age, diminished ovarian reserve, premature ovarian failure due to chemotherapy, autoimmune disorders, or surgical menopause. Women who convey a genetic mutation are also suitable candidates for Donor Egg IVF. Couples often turn to egg donation due to poor egg quality caused by advanced maternal age or premature ovarian failure. Donor egg IVF typically has higher success rates compared to traditional IVF, particularly for women with diminished ovarian reserve or poor egg quality. Those considering donor egg IVF should seek advice from reproductive specialists, fertility clinics, and legal professionals to fully comprehend the process, associated risks, and legal aspects involved.
The rise in delayed pregnancies, which is often linked to advanced maternal age, is a major contributing factor to infertility. Infertility is a significant global health concern that affects an increasing number of individuals and couples. A variety of factors, including lifestyle changes, environmental influences, and underlying health conditions, contribute to infertility, necessitating alternative fertility solutions. According to the World Health Organization, a large number of people experience infertility at some point in their lives, with around 17.5% of the adult population - approximately 1 in 6 worldwide - affected. This highlights the urgent need to increase access to affordable, high-quality fertility care for those in need. The overall increase in infertility rates globally is driving the upward demand for assisted reproductive technologies, such as Donor Egg IVF. Additionally, the growing awareness of fertility preservation, including the use of donor eggs, is creating opportunities for market growth. However, the high cost associated with Donor Egg IVF procedures can be a significant barrier for many individuals or couples, limiting their access to these services.
The Global Donor Egg IVF Services Market is segmented on the basis of Cycle Type, Application, and Region.
The market is divided into three categories based on Cycle Type: Fresh Donor Egg IVF Cycle and Frozen Donor Egg IVF Cycle. The market is largely dominated by the Frozen Donor Egg IVF Cycle. With frozen donor egg IVF cycles, there is increased flexibility in terms of timing, which allows for better coordination between the donor and recipient cycles. This advantage can greatly aid in planning and scheduling. Additionally, frozen donor egg IVF cycles tend to be more cost-effective when compared to traditional fresh donor egg cycles. Furthermore, the need for synchronization of cycles between the donor and recipient is eliminated.
The market is divided into two categories based on application: Fertility Clinics, Hospital, Surgical Centers and Clinical Research Institutes. The market is largely controlled by the Fertility Clinics sector. These clinics usually provide extensive programs for donor eggs, which encompass the evaluation and choice of egg donors, synchronization of cycles between donors and recipients, and the actual IVF procedure. Additionally, fertility clinics frequently offer counseling services to both egg donors and recipients, which encompass psychological assistance and guidance throughout the donation and IVF process.
The market for Donor Egg IVF Services is geographically widespread across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided into nations that contribute to the business. North America is expected to lead the market growth, owing to its advanced healthcare infrastructure and high success rate of IVF treatment. The United States and Canada, in particular, have well-established healthcare infrastructure, with continuous advancements in laboratory techniques, genetic testing, and cryopreservation contributing to the success of Donor Egg IVF Services. According to the center for Disease Control and Prevention 2021, Fertility Clinic Success Rates Report, 238,126 patients had 413,776 ART cycles attained at 453 reportage clinics in the US, resulting in 91,906 live births and 97,128 live-born infants. In the forecast period, Europe and Asia Pacific are projected to drive market growth due to advancements in Donor Egg IVF Technologies.
The market for donor egg IVF services is closely linked to fertility clinics, which play a crucial role in offering assisted reproductive technologies (ART) and facilitating the use of donor eggs for infertility treatment. Companies like Vitrolife, which specialize in assisted reproductive technologies, provide products and solutions for IVF procedures, including those involving donor eggs. These companies contribute to the technological aspects of the IVF process. Competition in the donor egg IVF market is driven by ongoing research and development efforts. Companies that invest in innovation, such as improving cryopreservation techniques or enhancing success rates, gain a competitive advantage. As an example, on December 17, 2021, Cooper Companies announced the completion of its acquisition of Generate Life Sciences, a foremost provider of donor egg and sperm for fertility performances, fertility cryopreservation facilities, as well as newborn stem cell storage (cord blood & cord tissue), for a purchase price of approximately USD1.6 billion.
In Feb. 2021, Cooper Surgical, a prominent player in the field of women's healthcare solutions, recently unveiled a long-term strategic partnership with Virtus Health, a renowned global provider of assisted reproductive services. This collaboration, which commenced in February 2021, aims to foster innovation, digitalization, and progress in the realm of fertility treatment. Infertility affects approximately 15% of couples worldwide, an estimated 48.5 million couples.